CG Oncology reported a gross margin of -239.24% and a net margin of -6,834.23% for the quarter ended Jun 2026. These financial ratios cover 13 quarters of results from Mar 2023 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Ratios | Mar2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | |||||||||||||
| Gross Margin | 100.00% | 100.00% | 100.00% | 5.34% | -32.21% | -173.50% | -239.24% | ||||||
| EBT Margin | -4,471.65% | -130,666.67% | -1,655,100.00% | -3,199.43% | -17,036.04% | -47,448.84% | -6,974.56% | -66,263.46% | -2,623.53% | -1,776.74% | -5,549.49% | -6,834.23% | |
| EBIT Margin | -5,010.82% | -156,033.33% | -1,935,500.00% | -4,247.45% | -23,290.99% | -65,802.33% | -8,344.08% | -81,161.54% | -3,068.97% | -2,097.33% | -6,130.10% | -7,467.68% | |
| EBITDA Margin | -5,010.82% | -156,033.33% | -1,935,500.00% | -4,247.45% | -23,290.99% | -65,802.33% | -8,344.08% | -81,161.54% | -3,068.97% | -2,097.33% | -6,130.10% | -7,467.68% | |
| Operating Margin | -5,010.82% | -156,033.33% | -1,935,500.00% | -4,247.45% | -23,290.99% | -65,802.33% | -8,344.08% | -81,161.54% | -3,068.97% | -2,097.33% | -6,130.10% | -7,467.68% | |
| Net Margin | -6,392.27% | -194,600.00% | -2,249,000.00% | -3,200.76% | -17,028.83% | -47,453.49% | -6,973.25% | -66,263.46% | -2,623.53% | -1,776.74% | -5,549.49% | -6,834.23% | |
| FCF Margin | -4,116.49% | -136,244.44% | -1,464,500.00% | -4,919.47% | -14,535.14% | -37,018.60% | -4,576.97% | -56,332.69% | -2,340.40% | -1,559.99% | -5,285.96% | -4,055.75% | |
| Efficiency | |||||||||||||
| Inventory AverageInventory Avg. | 1.53M | 1.53M | 1.25M | ||||||||||
| Assets AverageAssets Avg. | 389.20M | 571.72M | 558.40M | 653.63M | 741.49M | 714.81M | 715.68M | 760.75M | 963.43M | 1,110.46M | |||
| Invested CapitalInvested Cap. | 733.38M | 690.64M | 755.60M | 1,094.78M | 1,032.12M | ||||||||
| Asset Utilization RatioAsset Util. | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | |||
| Leverage & Solvency | |||||||||||||
| Debt Ratio | 0.00 | 0.00 | 0.00 | 0.00 | |||||||||
| Valuation | |||||||||||||
| Price to EarningsP/E | -122.03 | -111.33 | -124.88 | -56.37 | -54.17 | -47.85 | -72.14 | -81.21 | -99.11 | -79.35 | |||
| Price to SalesP/S | 0.00M | 0.02M | 0.06M | 0.00M | 0.04M | 0.00M | 0.00M | 0.01M | 0.01M | ||||
| Price to BookP/B | 3.63 | 3.81 | 4.75 | 2.44 | 2.65 | 2.96 | 4.59 | 4.45 | 5.46 | 6.10 | |||
| Enterprise Value | 1,499.64M | 1,551.57M | 2,007.49M | 1,050.41M | 1,178.23M | 1,320.98M | 2,472.75M | 2,608.06M | 4,880.12M | 5,245.89M | |||
| EV to EBIT | -66.74 | -60.02 | -70.95 | -27.61 | -27.92 | -27.10 | -48.36 | -53.55 | -73.51 | -60.72 | |||
| EV to EBITDA | -66.74 | -60.02 | -70.95 | -27.61 | -27.92 | -27.10 | -48.36 | -53.55 | -73.51 | -60.72 | |||
| Market Capitalization | 2,066.14M | 2,104.45M | 2,548.20M | 1,792.41M | 1,866.66M | 1,982.03M | 3,153.02M | 3,350.21M | 5,956.37M | 6,274.17M | |||
| Price to FCFP/FCF | -79.39 | -130.44 | -160.08 | -85.88 | -63.72 | -70.86 | -80.87 | -92.49 | -104.05 | -133.71 | |||
| EV to FCF | -57.63 | -96.17 | -126.11 | -50.33 | -40.22 | -47.22 | -63.42 | -72.00 | -85.25 | -111.79 | |||
| EV to CFO | -57.65 | -96.25 | -126.11 | -50.84 | -40.24 | -47.25 | -63.58 | -72.01 | -85.70 | -112.92 | |||
| Return Ratios | |||||||||||||
| Return on Sales [ROS]ROS | -5,010.82% | -156,033.33% | -1,935,500.00% | -4,247.45% | -23,290.99% | -65,802.33% | -8,344.08% | -81,161.54% | -28,546.10% | -3,068.97% | -2,097.33% | -6,130.10% | -7,467.68% |
| Return on Capital Employed [ROCE]ROCE | -17.98% | -14.60% | -17.68% | -18.14% | -18.70% | -22.98% | -26.29% | -26.14% | -23.16% | -23.76% | |||
| Return on Assets [ROA]ROA | -14.59% | -11.22% | -13.04% | -13.47% | -14.24% | -17.92% | -21.15% | -21.14% | -19.36% | -20.18% |